Sunday, April 19th, 2020
8:30 – 10:45
Plenary Session 5: Bench to Bedside: New insights Into Hemostasis and Cancer
Chairs: PM Sandset (Norway), R Giavazzi (Italy)
PL17 - Genetic and epigenetic regulation of cancer coagulome - lessons from heterogeneity of cancer cell populations
J Rak (Canada)
PL18 - Coagulation signaling and cancer immuno-therapy
W Ruf (Germany)
PL19 - Heparanase-revisited
Y Nadir (Israel)
PL20 - Cancer Animal Models in Thrombosis Research
C Dubois (France)
PL21 - The thrombin-inflammation axis in cancer progression
J Palumbo (USA)
Selected Abstract
10:45 – 11:45
Debate: Incidental VTE: To treat or not to treat?
Chairs: S Siragusa (Italy), S Middeldorp (The Netherlands)
YES: M Di Nisio (Italy)
NO: M Carrier (Canada)
11:45 - 12:45
Brunch
12:45 – 15:00
Plenary Session 6: Evolving Data for Treatment of VTE in cancer
Chairs: W Ageno (Italy), G Sof (USA)
PL22 - Anticoagulation in Cancer Patients: advantages and disadvantages
AJ Munoz (Spain)
PL23 - VTE management: emerging insights from the GARFIELD VTE registry
AJ Kakkar (UK)
PL24 - Treatment of VTE in cancer patients: from clinical trials to real life
G Agnelli (Italy)
PL25 - VTE in Palliative Care Patients: What do we know?
S Noble (UK)
Selected Abstract
15:00 - 15:15
Concluding Remarks